Jasper Therapeutics
JSPR
40 hedge funds and large institutions have $64.1M invested in Jasper Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 7 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 39 → 40 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9.22% less ownership
Funds ownership: 82.62% → 73.41% (-9.2%)
48% less capital inflows, than outflows
Capital inflows: $7.47M | Capital outflows: $14.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.67M |
| 2 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.05M |
| 3 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$969K |
| 4 |
Morgan Stanley
New York
|
+$616K |
| 5 |
Landscape Capital Management
Englewood,
New Jersey
|
+$530K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$6.93M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.15M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.01M |
| 4 |
Woodline Partners
San Francisco,
California
|
-$850K |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$788K |
JSPR Hedge Fund Activity: Q4 2023 in Review
40 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2023, worth a combined $64.1M — up 0.55% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JSPR positions and 7 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.67M. The largest seller was BVF Inc, exiting entirely with an estimated $6.93M sold.
- 40 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2023, up from 39 in Q3 2023.
- Funds reported $64.1M of Jasper Therapeutics stock for Q4 2023, up 0.55% quarter-over-quarter.
- 8 funds opened new Jasper Therapeutics positions in Q4 2023 and 7 closed out, a net change of +1 holder.
- The largest Jasper Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.67M added.
- The largest Jasper Therapeutics seller in Q4 2023 was BVF Inc, an estimated $6.93M sold.
Based on aggregated 13F filings for Q4 2023.